Top

Published in:

01-08-2021 | Hepatitis | Review

The role of natural killer cells in liver inflammation

Authors: A. J. Highton, I. S. Schuster, M. A. Degli-Esposti, M. Altfeld

Published in: Seminars in Immunopathology | Issue 4/2021

Abstract

The liver is an important immunological site that can promote immune tolerance or activation. Natural killer (NK) cells are a major immune subset within the liver, and therefore understanding their role in liver homeostasis and inflammation is crucial. Due to their cytotoxic function, NK cells are important in the immune response against hepatotropic viral infections but are also involved in the inflammatory processes of autoimmune liver diseases and fatty liver disease. Whether NK cells primarily promote pro-inflammatory or tolerogenic responses is not known for many liver diseases. Understanding the involvement of NK cells in liver inflammation will be crucial in effective treatment and future immunotherapeutic targeting of NK cells in these disease settings. Here, we explore the role that NK cells play in inflammation of the liver in the context of viral infection, autoimmunity and fatty liver disease.

Freitas-Lopes M, Mafra K, David B, Carvalho-Gontijo R, Menezes G (2017) Differential location and distribution of hepatic immune cells. Cells 6:48. https://doi.org/10.3390/cells6040048CrossRefPubMedCentral

Tanimine N, Tanaka Y, Abe T, Piao J, Chayama K, Ohdan H (2016) Functional behavior of NKp46-positive intrahepatic natural killer cells against hepatitis C virus reinfection after liver transplantation. Transplantation 100:355–364. https://doi.org/10.1097/TP.0000000000001031CrossRefPubMed

Lam VC, Lanier LL (2017) NK cells in host responses to viral infections. Curr Opin Immunol 44:43–51. https://doi.org/10.1016/j.coi.2016.11.003CrossRefPubMed

Gao B, Radaeva S, Park O (2009) Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 86:513–528. https://doi.org/10.1189/JLB.0309135CrossRefPubMedPubMedCentral

Liu P, Chen L, Zhang H (2018) Natural killer cells in liver disease and hepatocellular carcinoma and the nk cell-based immunotherapy. J Immunol Res 2018:1–8. https://doi.org/10.1155/2018/1206737CrossRef

Juengpanich S, Shi L, Iranmanesh Y, Chen J, Cheng Z, Khoo AKJ, Pan L, Wang Y, Cai X (2019) The role of natural killer cells in hepatocellular carcinoma development and treatment: a narrative review. Transl Oncol 12:1092–1107. https://doi.org/10.1016/j.tranon.2019.04.021CrossRefPubMedPubMedCentral

Braud VM, Allan DSJ, O’Callaghan CA et al (1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391:795–799. https://doi.org/10.1038/35869CrossRefPubMed

Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL (1993) HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci 90:12000–12004. https://doi.org/10.1073/pnas.90.24.12000CrossRefPubMedPubMedCentral

Colonna M, Spies T, Strominger JL, Ciccone E, Moretta A, Moretta L, Pende D, Viale O (1992) Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene. Proc Natl Acad Sci 89:7983–7985. https://doi.org/10.1073/pnas.89.17.7983CrossRefPubMedPubMedCentral

10.

Biassoni R, Falco M, Cambiaggi A, Costa P, Verdiani S, Pende D, Conte R, di Donato C, Parham P, Moretta L (1995) Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by “group 2” or “group 1” NK clones. J Exp Med 182:605–609. https://doi.org/10.1084/jem.182.2.605CrossRefPubMed

11.

Kumar S (2018) Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology 154:383–393. https://doi.org/10.1111/imm.12921CrossRefPubMedPubMedCentral

12.

Peng H, Tian Z (2017) Diversity of tissue-resident NK cells. Semin Immunol 31:3–10. https://doi.org/10.1016/j.smim.2017.07.006CrossRefPubMed

13.

Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M, Hong M, Bertoletti A, Bicciato S, Invernizzi P, Lugli E, Torzilli G, Gershwin ME, Mavilio D (2016) Human liver-resident CD56bright/CD16neg NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun 66:40–50. https://doi.org/10.1016/j.jaut.2015.08.011CrossRefPubMed

14.

Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633–640. https://doi.org/10.1016/S1471-4906(01)02060-9CrossRefPubMed

15.

Moroso V, Metselaar HJ, Mancham S, Tilanus HW, Eissens D, van der Meer A, van der Laan LJW, Kuipers EJ, Joosten I, Kwekkeboom J (2010) Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transpl 16:895–908. https://doi.org/10.1002/lt.22080CrossRefPubMed

16.

Bankovich AJ, Shiow LR, Cyster JG (2010) CD69 Suppresses sphingosine 1-phosophate receptor-1 (S1P1) function through interaction with membrane helix 4. J Biol Chem 285:22328–22337. https://doi.org/10.1074/jbc.M110.123299CrossRefPubMedPubMedCentral

17.

Bank I, Book M, Ware R (1994) Functional role of VLA-1 (CD49A) in adhesion, cation-dependent spreading, and activation of cultured human T lymphocytes. Cell Immunol 156:424–437. https://doi.org/10.1006/cimm.1994.1187CrossRefPubMed

18.

Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, Christophides T, Pallett LJ, Peppa D, Dunn C, Fusai G, Male V, Davidson BR, Kennedy P, Maini MK (2016) CXCR6 marks a novel subset of T-betloEomeshi natural killer cells residing in human liver. Sci Rep 6:26157. https://doi.org/10.1038/srep26157CrossRefPubMedPubMedCentral

19.

Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, Kubota M, Matsumoto R, Thapa P, Szabo PA, Li Poon MM, Li J, Arakawa-Hoyt J, Shen Y, Fong L, Lanier LL, Farber DL (2020) Tissue determinants of human nk cell development, function, and residence. Cell 180:749–763.e13. https://doi.org/10.1016/j.cell.2020.01.022CrossRefPubMedPubMedCentral

20.

Takeda K, Cretney E, Hayakawa Y, Ota T, Akiba H, Ogasawara K, Yagita H, Kinoshita K, Okumura K, Smyth MJ (2005) TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood 105:2082–2089. https://doi.org/10.1182/blood-2004-08-3262CrossRefPubMed

21.

Vivier E, Artis D, Colonna M, Diefenbach A, di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie ANJ, Mebius RE, Powrie F, Spits H (2018) Innate lymphoid cells: 10 years on. Cell 174:1054–1066. https://doi.org/10.1016/j.cell.2018.07.017CrossRefPubMed

22.

Daussy C, Faure F, Mayol K, Viel S, Gasteiger G, Charrier E, Bienvenu J, Henry T, Debien E, Hasan UA, Marvel J, Yoh K, Takahashi S, Prinz I, de Bernard S, Buffat L, Walzer T (2014) T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. J Exp Med 211:563–577. https://doi.org/10.1084/jem.20131560CrossRefPubMedPubMedCentral

23.

Mackay LK, Minnich M, Kragten NAM, Liao Y, Nota B, Seillet C, Zaid A, Man K, Preston S, Freestone D, Braun A, Wynne-Jones E, Behr FM, Stark R, Pellicci DG, Godfrey DI, Belz GT, Pellegrini M, Gebhardt T, Busslinger M, Shi W, Carbone FR, van Lier RAW, Kallies A, van Gisbergen KPJM (2016) Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes. Science (80-) 352:459–463. https://doi.org/10.1126/science.aad2035CrossRef

24.

Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, Sun JC, Lindsten T, Reiner SL (2012) The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 36:55–67. https://doi.org/10.1016/j.immuni.2011.11.016CrossRefPubMedPubMedCentral

25.

Bai L, Vienne M, Tang L, Kerdiles Y, Etiennot M, Escalière B, Galluso J, Wei H, Sun R, Vivier E, Peng H, Tian Z (2021) Liver type 1 innate lymphoid cells develop locally via an interferon-γ–dependent loop. Science (80-) 371:eaba4177. https://doi.org/10.1126/science.aba4177CrossRef

26.

Peng H, Jiang X, Chen Y, Sojka DK, Wei H, Gao X, Sun R, Yokoyama WM, Tian Z (2013) Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J Clin Invest 123:1444–1456. https://doi.org/10.1172/JCI66381CrossRefPubMedPubMedCentral

27.

El Weizman O, Adams NM, Schuster IS et al (2017) ILC1 confer early host protection at initial sites of viral infection. Cell 171:795–808.e12. https://doi.org/10.1016/j.cell.2017.09.052CrossRefPubMedPubMedCentral

28.

Cuff AO, Robertson FP, Stegmann KA, Pallett LJ, Maini MK, Davidson BR, Male V (2016) Eomes hi NK cells in human liver are long-lived and do not recirculate but can be replenished from the circulation. J Immunol 197:4283–4291. https://doi.org/10.4049/jimmunol.1601424CrossRefPubMedPubMedCentral

29.

Marquardt N, Béziat V, Nyström S, et al (2015) Cutting edge: identification and characterization of human intrahepatic CD49a⁺NK Cells. J Immunol 194:2467–2471. https://doi.org/10.4049/jimmunol.1402756

30.

Paust S, Gill HS, Wang B-Z, Flynn MP, Moseman EA, Senman B, Szczepanik M, Telenti A, Askenase PW, Compans RW, von Andrian UH (2010) Critical role for the chemokine receptor CXCR6 in NK cell–mediated antigen-specific memory of haptens and viruses. Nat Immunol 11:1127–1135. https://doi.org/10.1038/ni.1953CrossRefPubMedPubMedCentral

31.

Tu Z, Bozorgzadeh A, Pierce RH, Kurtis J, Crispe IN, Orloff MS (2008) TLR-dependent cross talk between human Kupffer cells and NK cells. J Exp Med 205:233–244. https://doi.org/10.1084/jem.20072195CrossRefPubMedPubMedCentral

32.

Lassen MG, Lukens JR, Dolina JS, Brown MG, Hahn YS (2010) Intrahepatic IL-10 maintains NKG2A + Ly49 − liver NK cells in a functionally hyporesponsive state. J Immunol 184:2693–2701. https://doi.org/10.4049/jimmunol.0901362CrossRefPubMed

33.

Chong WP, Zhou J, Law HKW, Tu W, Lau YL (2010) Natural killer cells become tolerogenic after interaction with apoptotic cells. Eur J Immunol 40:1718–1727. https://doi.org/10.1002/eji.200939768CrossRefPubMed

34.

Zhou J, Peng H, Li K, Qu K, Wang B, Wu Y, Ye L, Dong Z, Wei H, Sun R, Tian Z (2019) Liver-resident NK cells control antiviral activity of hepatic T cells via the PD-1-PD-L1 axis. Immunity 50:403–417.e4. https://doi.org/10.1016/j.immuni.2018.12.024CrossRefPubMed

35.

Nabekura T, Riggan L, Hildreth AD, O’Sullivan TE, Shibuya A (2020) Type 1 innate lymphoid cells protect mice from acute liver injury via interferon-γ secretion for upregulating Bcl-xL expression in hepatocytes. Immunity 52:96–108.e9. https://doi.org/10.1016/j.immuni.2019.11.004CrossRefPubMed

36.

Sun R, Gao B (2004) Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-γ). Gastroenterology 127:1525–1539. https://doi.org/10.1053/j.gastro.2004.08.055CrossRefPubMed

37.

Horras CJ, Lamb CL, Mitchell KA (2011) Regulation of hepatocyte fate by interferon-γ. Cytokine Growth Factor Rev 22:35–43. https://doi.org/10.1016/j.cytogfr.2011.01.001CrossRefPubMedPubMedCentral

38.

Alizadeh AHM, Shahnazi A, Rasoulzadeh A, Shams E, Mohammadi M, Darabi F, Behdad M (2012) Characteristic findings of primary sclerosing cholangitis on endoscopic retrograde cholangiography: Which is the Most Common Finding? Clin Med Insights Gastroenterol 5:CGast.S7850. https://doi.org/10.4137/CGast.S7850CrossRef

39.

Chuang YH, Lian ZX, Tsuneyama K et al (2006) Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun 26:232–240. https://doi.org/10.1016/j.jaut.2006.04.001CrossRefPubMed

40.

Shimoda S, Harada K, Niiro H et al (2011) Interaction between toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology 53:1270–1281. https://doi.org/10.1002/hep.24194CrossRefPubMed

41.

Shimoda S, Hisamoto S, Harada K, Iwasaka S, Chong Y, Nakamura M, Bekki Y, Yoshizumi T, Shirabe K, Ikegami T, Maehara Y, He XS, Gershwin ME, Akashi K (2015) Natural killer cells regulate T cell immune responses in primary biliary cirrhosis. Hepatology 62:1817–1827. https://doi.org/10.1002/hep.28122CrossRefPubMed

42.

Hydes TJ, Blunt MD, Naftel J, Vallejo AF, Seumois G, Wang A, Vijayanand P, Polak ME, Khakoo SI (2019) Constitutive activation of natural killer cells in primary biliary cholangitis. Front Immunol 10:1–12. https://doi.org/10.3389/fimmu.2019.02633CrossRef

43.

Weismüller TJ, Strassburg CP, Trivedi PJ et al (2017) Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 152:1975–1984.e8. https://doi.org/10.1053/j.gastro.2017.02.038CrossRefPubMed

44.

Lunder AK, Hov JR, Borthne A, Gleditsch J, Johannesen G, Tveit K, Viktil E, Henriksen M, Hovde Ø, Huppertz-Hauss G, Høie O, Høivik ML, Monstad I, Solberg IC, Jahnsen J, Karlsen TH, Moum B, Vatn M, Negård A (2016) Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology 151:660–669.e4. https://doi.org/10.1053/j.gastro.2016.06.021CrossRefPubMed

45.

Karlsen TH, Boberg KM, Olsson M, Sun JY, Senitzer D, Bergquist A, Schrumpf E, Thorsby E, Lie BA (2007) Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol 46:899–906. https://doi.org/10.1016/j.jhep.2007.01.032CrossRefPubMed

46.

Berglin L, Bergquist A, Johansson H, Glaumann H, Jorns C, Lunemann S, Wedemeyer H, Ellis EC, Björkström NK (2014) In situ characterization of intrahepatic non-parenchymal cells in PSC reveals phenotypic patterns associated with disease severity. PLoS One 9:1–11. https://doi.org/10.1371/journal.pone.0105375CrossRef

47.

Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, Horani A, Nassar M, Friedman SL, Safadi R (2006) Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 45:60–71. https://doi.org/10.1016/j.jhep.2005.12.025CrossRefPubMed

48.

Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B (2006) Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130:435–452. https://doi.org/10.1053/j.gastro.2005.10.055CrossRefPubMed

49.

Glässner A, Eisenhardt M, Krämer B, Körner C, Coenen M, Sauerbruch T, Spengler U, Nattermann J (2012) NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL-and NKG2D-dependent manner. Lab Investig 92:967–977. https://doi.org/10.1038/labinvest.2012.54CrossRefPubMed

50.

Gur C, Doron S, Kfir-Erenfeld S, Horwitz E, Abu-tair L, Safadi R, Mandelboim O (2012) NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut 61:885–893. https://doi.org/10.1136/gutjnl-2011-301400CrossRefPubMed

51.

Langeneckert AE, Lunemann S, Martrus G, Salzberger W, Hess LU, Ziegler AE, Poch T, Ravichandran G, Matschl U, Bosse JB, Tiegs G, Fischer L, Koch M, Herkel J, Oldhafer KJ, Schramm C, Altfeld M (2019) CCL21-expression and accumulation of CCR7 + NK cells in livers of patients with primary sclerosing cholangitis. Eur J Immunol 49:758–769. https://doi.org/10.1002/eji.201847965CrossRefPubMed

52.

Grant AJ, Goddard S, Ahmed-Choudhury J, Reynolds G, Jackson DG, Briskin M, Wu L, Hübscher SG, Adams DH (2002) Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am J Pathol 160:1445–1455. https://doi.org/10.1016/S0002-9440(10)62570-9CrossRefPubMedPubMedCentral

53.

Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, Lohse AW, Montano-Loza AJ (2018) Autoimmune hepatitis. Nat Rev Dis Prim 4:1–22. https://doi.org/10.1038/nrdp.2018.17CrossRef

54.

Strassburg C, Obermayer-Straub P, Alex B, Durazzo M, Rizzetto M, Tukey RH, Manns MP (1996) Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 111:1576–1586. https://doi.org/10.1016/S0016-5085(96)70020-3CrossRefPubMed

55.

Martini E, Abuaf N, Cavalli F, Durand VÉR, Johanet C, Homberg JC (1988) Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 8:1662–1666. https://doi.org/10.1002/hep.1840080632CrossRefPubMed

56.

Homberg J-C, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Lévy VG, Grippon P, Opolon P, Bernuau J, Benhamou JP, Alagille D (1987) Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology 7:1333–1339. https://doi.org/10.1002/hep.1840070626CrossRefPubMed

57.

Johnson G, Holborow E, Glynn L (1965) Antibody to smooth muscle in patients with liver disease. Lancet 286:878–879. https://doi.org/10.1016/S0140-6736(65)92505-5CrossRef

58.

Puustinen L, Barner-Rasmussen N, Pukkala E, Färkkilä M (2019) Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: a nationwide register-based cohort study in Finland. Dig Liver Dis 51:1294–1299. https://doi.org/10.1016/j.dld.2019.01.015CrossRefPubMed

59.

Umemura T, Joshita S, Saito H, Yoshizawa K, Norman GL, Tanaka E, Ota M (2019) KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis. JHEP Reports 1:353–360. https://doi.org/10.1016/j.jhepr.2019.09.003CrossRefPubMedPubMedCentral

60.

Littera R, Chessa L, Onali S, Figorilli F, Lai S, Secci L, la Nasa G, Caocci G, Arras M, Melis M, Cappellini S, Balestrieri C, Serra G, Conti M, Zolfino T, Casale M, Casu S, Pasetto MC, Barca L, Salustro C, Matta L, Scioscia R, Zamboni F, Faa G, Orrù S, Carcassi C (2016) Exploring the role of killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis. PLoS One 11:2–15. https://doi.org/10.1371/journal.pone.0146086CrossRef

61.

Yamazaki T, Umemura T, Joshita S, Yoshizawa K, Tanaka E, Ota M (2018) A cis-eQTL of HLA-DPB1 affects susceptibility to type 1 autoimmune hepatitis. Sci Rep 8:11924. https://doi.org/10.1038/s41598-018-30406-9CrossRefPubMedPubMedCentral

62.

Niehrs A, Garcia-Beltran WF, Norman PJ, Watson GM, Hölzemer A, Chapel A, Richert L, Pommerening-Röser A, Körner C, Ozawa M, Martrus G, Rossjohn J, Lee JH, Berry R, Carrington M, Altfeld M (2019) A subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44. Nat Immunol 20:1129–1137. https://doi.org/10.1038/s41590-019-0448-4CrossRefPubMedPubMedCentral

63.

Dong Z, Wei H, Sun R, Hu Z, Gao B, Tian Z (2004) Involvement of natural killer cells in PolyI:C-induced liver injury. J Hepatol 41:966–973. https://doi.org/10.1016/j.jhep.2004.08.021CrossRefPubMed

64.

Jeffery HC, Braitch MK, Bagnall C, Hodson J, Jeffery LE, Wawman RE, Wong LL, Birtwistle J, Bartlett H, Lohse AW, Hirschfield GM, Dyson J, Jones D, Hubscher SG, Klenerman P, Adams DH, Oo YH (2018) Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis. Hepatol Commun 2:421–436. https://doi.org/10.1002/hep4.1163CrossRefPubMedPubMedCentral

65.

Xiao F, Ai G, Yan W, Wan X, Luo X, Ning Q (2018) Intrahepatic recruitment of cytotoxic NK cells contributes to autoimmune hepatitis progression. Cell Immunol 327:13–20. https://doi.org/10.1016/j.cellimm.2017.12.008CrossRefPubMed

66.

Melnick JL, Howard CR (1994) Classification and taxonomy of hepatitis viruses: summary of a workshop. In: Nishioka K, Suzuki H, Mishiro S, Oda T (eds) Viral Hepatitis and Liver Disease. Springer Japan, Tokyo, pp 47–49CrossRef

67.

WHO (2017) Executive summary - global hepatitis report, 2017. World Heal Organ

68.

Zhao J, Li Y, Jin L, Zhang S, Fan R, Sun Y, Zhou C, Shang Q, Li W, Zhang Z, Wang FS (2012) Natural killer cells are characterized by the concomitantly increased interferon-γ and cytotoxicity in acute resolved hepatitis B patients. PLoS One 7:e49135. https://doi.org/10.1371/journal.pone.0049135CrossRefPubMedPubMedCentral

69.

Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Orlandini A, Sacchelli L, Missale G, Ferrari C (2009) Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58:974–982. https://doi.org/10.1136/gut.2008.163600CrossRefPubMed

70.

Yu W-H, Cosgrove C, Berger CT et al (2018) ADCC-mediated CD56dim NK cell responses are associated with early HBsAg clearance in acute HBV infection. Pathog Immun 3:2. https://doi.org/10.20411/pai.v3i1.288CrossRefPubMedPubMedCentral

71.

Zheng M, Sun R, Wei H, Tian Z (2016) NK cells help induce anti–hepatitis B virus CD8 + T cell immunity in mice. J Immunol 196:4122–4131. https://doi.org/10.4049/jimmunol.1500846CrossRefPubMed

72.

Lunemann S, Malone DFG, Hengst J, Port K, Grabowski J, Deterding K, Markova A, Bremer B, Schlaphoff V, Cornberg M, Manns MP, Sandberg JK, Ljunggren HG, Björkström NK, Wedemeyer H (2014) Compromised function of natural killer cells in acute and chronic viral hepatitis. J Infect Dis 209:1362–1373. https://doi.org/10.1093/infdis/jit561CrossRefPubMed

73.

Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D, de Filippi F, Bruno S, Mondelli MU (2009) Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137:1151–1160.e7. https://doi.org/10.1053/j.gastro.2009.05.047CrossRefPubMed

74.

Wijaya RS, Read SA, Schibeci S, Han S, Azardaryany MK, Poorten D, Lin R, Yuen L, Lam V, Douglas MW, George J, Ahlenstiel G (2021) Expansion of dysfunctional CD56-CD16+ NK cells in chronic hepatitis B patients. Liver Int 41:969–981. https://doi.org/10.1111/liv.14784CrossRefPubMed

75.

Peppa D, Micco L, Javaid A, Kennedy PTF, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, Gilson RJ, Maini MK (2010) Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 6:e1001227. https://doi.org/10.1371/journal.ppat.1001227CrossRefPubMedPubMedCentral

76.

Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z, Wei H (2012) TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog 8:e1002594. https://doi.org/10.1371/journal.ppat.1002594CrossRefPubMedPubMedCentral

77.

Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini MK (2007) Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage. J Exp Med 204:667–680. https://doi.org/10.1084/jem.20061287CrossRefPubMedPubMedCentral

78.

Jiang Y, Qin S, Wei X, Liu X, Guan J, Zhu H, Chang G, Chen Y, Lu H, Qian J, Wang Z, Shen M, Lin X (2021) Highly activated TRAIL+ CD56bright NK cells are associated with the liver damage in HBV-LC patients. Immunol Lett 232:9–19. https://doi.org/10.1016/j.imlet.2020.12.008CrossRefPubMed

79.

Peppa D, Gill US, Reynolds G, Easom NJW, Pallett LJ, Schurich A, Micco L, Nebbia G, Singh HD, Adams DH, Kennedy PTF, Maini MK (2013) Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell–mediated deletion. J Exp Med 210:99–114. https://doi.org/10.1084/jem.20121172CrossRefPubMedPubMedCentral

80.

Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM, Alexander GJ, Cramp ME, O'Brien SJ, Rosenberg WM, Thomas DL, Carrington M (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (80-) 305:872–874. https://doi.org/10.1126/science.1097670CrossRef

81.

Lunemann S, Schöbel A, Kah J, Fittje P, Hölzemer A, Langeneckert AE, Hess LU, Poch T, Martrus G, Garcia-Beltran WF, Körner C, Ziegler AE, Richert L, Oldhafer KJ, Schulze zur Wiesch J, Schramm C, Dandri M, Herker E, Altfeld M (2018) Interactions between KIR3DS1 and HLA-F activate natural killer cells to control HCV replication in cell culture. Gastroenterology 155:1366–1371.e3. https://doi.org/10.1053/j.gastro.2018.07.019CrossRefPubMed

82.

Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, Ahmed P, Missale G, Ferrari C, Khakoo SI (2010) Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 138:1536–1545. https://doi.org/10.1053/j.gastro.2010.01.006CrossRefPubMed

83.

Hengst J, Klein AL, Lunemann S, Deterding K, Hardtke S, Falk CS, Manns MP, Cornberg M, Schlaphoff V, Wedemeyer H (2018) Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection. J Viral Hepat 26:jvh.13050. https://doi.org/10.1111/jvh.13050CrossRef

84.

Alter G, Jost S, Rihn S, Reyor LL, Nolan BE, Ghebremichael M, Bosch R, Altfeld M, Lauer GM (2011) Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. J Hepatol 55:278–288. https://doi.org/10.1016/j.jhep.2010.11.030CrossRefPubMed

85.

Golden-Mason L, Madrigal-Estebas L, McGrath E, Conroy MJ, Ryan EJ, Hegarty JE, O'Farrelly C, Doherty DG (2008) Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 57:1121–1128. https://doi.org/10.1136/gut.2007.130963CrossRefPubMed

86.

Ahlenstiel G, Titerence RH, Koh C, Edlich B, Feld JJ, Rotman Y, Ghany MG, Hoofnagle JH, Liang TJ, Heller T, Rehermann B (2010) Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa–dependent manner. Gastroenterology 138:325–335.e2. https://doi.org/10.1053/j.gastro.2009.08.066CrossRefPubMed

87.

Jinushi M, Takehara T, Tatsumi T, Kanto T, Miyagi T, Suzuki T, Kanazawa Y, Hiramatsu N, Hayashi N (2004) Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered nk cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 173:6072–6081. https://doi.org/10.4049/jimmunol.173.10.6072CrossRefPubMed

88.

Zhang C, Wang X, Li S, Twelkmeyer T, Wang WH, Zhang SY, Wang SF, Chen JZ, Jin X, Wu YZ, Chen XW, Wang SD, Niu JQ, Chen HR, Tang H (2019) NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun 10:1507. https://doi.org/10.1038/s41467-019-09212-yCrossRefPubMedPubMedCentral

89.

Strunz B, Hengst J, Deterding K, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Björkström NK (2018) Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. Nat Commun 9:2275. https://doi.org/10.1038/s41467-018-04685-9CrossRefPubMedPubMedCentral

90.

Doyle EH, Aloman C, El-Shamy A et al (2021) A subset of liver resident natural killer cells is expanded in hepatitis C-infected patients with better liver function. Sci Rep 11:1551. https://doi.org/10.1038/s41598-020-80819-8CrossRefPubMedPubMedCentral

91.

Noor A, Panwala A, Forouhar F, Wu GY (2018) Hepatitis caused by herpes viruses: a review. J Dig Dis 19:446–455. https://doi.org/10.1111/1751-2980.12640CrossRefPubMed

92.

Tay CH, Welsh RM (1997) Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol 71:267–275. https://doi.org/10.1128/JVI.71.1.267-275.1997CrossRefPubMedPubMedCentral

93.

Sumaria N, Dommelen SLH, Andoniou CE, Smyth MJ, Scalzo AA, Degli-Esposti MA (2009) The roles of interferon-γ and perforin in antiviral immunity in mice that differ in genetically determined NK-cell-mediated antiviral activity. Immunol Cell Biol 87:559–566. https://doi.org/10.1038/icb.2009.41CrossRefPubMed

94.

van Dommelen SLH, Sumaria N, Schreiber RD, Scalzo AA, Smyth MJ, Degli-Esposti MA (2006) Perforin and Granzymes have distinct roles in defensive immunity and immunopathology. Immunity 25:835–848. https://doi.org/10.1016/j.immuni.2006.09.010CrossRefPubMed

95.

Ali AK, Komal AK, Almutairi SM, Lee S-H (2019) Natural killer cell-derived IL-10 prevents liver damage during sustained murine cytomegalovirus infection. Front Immunol 10:1–14. https://doi.org/10.3389/fimmu.2019.02688CrossRef

96.

Lee S-H, Kim K-S, Fodil-Cornu N, Vidal SM, Biron CA (2009) Activating receptors promote NK cell expansion for maintenance, IL-10 production, and CD8 T cell regulation during viral infection. J Exp Med 206:2235–2251. https://doi.org/10.1084/jem.20082387CrossRefPubMedPubMedCentral

97.

Lopez-Vergès S, Milush JM, Schwartz BS, et al (2011) Expansion of a unique CD57+NKG2C hi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA 108:14725–14732. https://doi.org/10.1073/pnas.1110900108

98.

Gumá M, Angulo A, Vilches C et al (2004) Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104:3664–3671. https://doi.org/10.1182/blood-2004-05-2058CrossRefPubMed

99.

Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, Lopez-Vergès S, Lanier LL, Weisdorf D, Miller JS (2012) Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119:2665–2674. https://doi.org/10.1182/blood-2011-10-386995CrossRefPubMedPubMedCentral

100.

Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, Braun F, Lu S, Pfefferle S, Schröder AS, Edler C, Gross O, Glatzel M, Wichmann D, Wiech T, Kluge S, Pueschel K, Aepfelbacher M, Huber TB (2020) Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med 383:590–592. https://doi.org/10.1056/NEJMc2011400CrossRefPubMed

101.

Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP, Landry DW (2020) Extrapulmonary manifestations of COVID-19. Nat Med 26:1017–1032. https://doi.org/10.1038/s41591-020-0968-3CrossRefPubMed

102.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71:732–739. https://doi.org/10.1093/cid/ciaa237CrossRefPubMed

103.

Zhang C, Shi L, Wang F-S (2020) Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 5:428–430. https://doi.org/10.1016/S2468-1253(20)30057-1CrossRefPubMedPubMedCentral

104.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5CrossRefPubMedPubMedCentral

105.

Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720. https://doi.org/10.1056/NEJMoa2002032CrossRefPubMed

106.

Lagana SM, De Michele S, Lee MJ et al (2020) COVID-19–associated hepatitis complicating recent living donor liver transplantation. Arch Pathol Lab Med 144:929–932. https://doi.org/10.5858/arpa.2020-0186-SACrossRef

107.

Wang C, Xu J, Wang S, Pan S, Zhang J, Han Y, Huang M, Wu D, Yang Q, Yang X, Yang Y, Shu T, Zou X, Li R, Luo Y, Yao R, Wang Y, Qiu Y, Wang Y, Zhang DY, Yao Q, Yan Y, Zhou X, Shang Y (2020) Imaging mass cytometric analysis of postmortem tissues reveals dysregulated immune cell and cytokine responses in multiple organs of COVID-19 patients. Front Microbiol 11:600989. https://doi.org/10.3389/fmicb.2020.600989CrossRefPubMedPubMedCentral

108.

Maucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, Strunz B, Lentini A, Reinius B, Brownlie D, Gomez AC, Ask EH, Hull RM, Haroun-Izquierdo A, Schaffer M, Klingström J, Folkesson E, Buggert M, Sandberg JK, Eriksson LI, Rooyackers O, Ljunggren HG, Malmberg KJ, Michaëlsson J, Marquardt N, Hammer Q, Strålin K, Björkström NK, Karolinska COVID-19 Study Group‡ (2020) Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol 5:eabd6832. https://doi.org/10.1126/sciimmunol.abd6832CrossRefPubMedPubMedCentral

109.

Zheng M, Gao Y, Wang G, et al (2020) Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 17:533–535. https://doi.org/10.1038/s41423-020-0402-2

110.

Osman M, Faridi RM, Sligl W, Shabani-Rad MT, Dharmani-Khan P, Parker A, Kalra A, Tripathi MB, Storek J, Cohen Tervaert JW, Khan FM (2020) Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19. Blood Adv 4:5035–5039. https://doi.org/10.1182/bloodadvances.2020002650CrossRefPubMedPubMedCentral

111.

Neeland MR, Bannister S, Clifford V, Dohle K, Mulholland K, Sutton P, Curtis N, Steer AC, Burgner DP, Crawford NW, Tosif S, Saffery R (2021) Innate cell profiles during the acute and convalescent phase of SARS-CoV-2 infection in children. Nat Commun 12:1084. https://doi.org/10.1038/s41467-021-21414-xCrossRefPubMedPubMedCentral

112.

Gomez-Santos L, Luka Z, Wagner C, Fernandez-Alvarez S, Lu SC, Mato JM, Martinez-Chantar ML, Beraza N (2012) Inhibition of natural killer cells protects the liver against acute injury in the absence of glycine N-methyltransferase. Hepatology 56:747–759. https://doi.org/10.1002/hep.25694CrossRefPubMed

113.

Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, Wedemeyer I, Marquitan G, Gieseler RK, Baba HA, Gerken G, Canbay A (2010) Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology 51:92–102. https://doi.org/10.1002/hep.23253CrossRefPubMed

114.

Cepero-Donates Y, Lacraz G, Ghobadi F, Rakotoarivelo V, Orkhis S, Mayhue M, Chen YG, Rola-Pleszczynski M, Menendez A, Ilangumaran S, Ramanathan S (2016) Interleukin-15-mediated inflammation promotes non-alcoholic fatty liver disease. Cytokine 82:102–111. https://doi.org/10.1016/j.cyto.2016.01.020CrossRefPubMed

115.

Tosello-Trampont AC, Krueger P, Narayanan S, Landes SG, Leitinger N, Hahn YS (2016) NKp46+ natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice. Hepatology 63:799–812. https://doi.org/10.1002/hep.28389CrossRefPubMed

116.

Krämer B, Körner C, Kebschull M, Glässner A, Eisenhardt M, Nischalke HD, Alexander M, Sauerbruch T, Spengler U, Nattermann J (2012) Natural killer p46 High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology 56:1201–1213. https://doi.org/10.1002/hep.25804CrossRefPubMed

117.

Stiglund N, Strand K, Cornillet M, Stål P, Thorell A, Zimmer CL, Näslund E, Karlgren S, Nilsson H, Mellgren G, Fernø J, Hagström H, Björkström NK (2019) Retained NK cell phenotype and functionality in non-alcoholic fatty liver disease. Front Immunol 10:1–13. https://doi.org/10.3389/fimmu.2019.01255CrossRef

118.

Diedrich T, Kummer S, Galante A, Drolz A, Schlicker V, Lohse AW, Kluwe J, Eberhard JM, Schulze zur Wiesch J (2020) Characterization of the immune cell landscape of patients with NAFLD. PLoS One 15:1–16. https://doi.org/10.1371/journal.pone.0230307CrossRef

119.

Michelet X, Dyck L, Hogan A, Loftus RM, Duquette D, Wei K, Beyaz S, Tavakkoli A, Foley C, Donnelly R, O’Farrelly C, Raverdeau M, Vernon A, Pettee W, O’Shea D, Nikolajczyk BS, Mills KHG, Brenner MB, Finlay D, Lynch L (2018) Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol 19:1330–1340. https://doi.org/10.1038/s41590-018-0251-7CrossRefPubMed

120.

Thakur A, Pedersen LE, Jungersen G (2012) Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 30:4907–4920. https://doi.org/10.1016/j.vaccine.2012.05.049CrossRefPubMed

121.

Zhao J, Zhang Z, Luan Y, Zou Z, Sun Y, Li Y, Jin L, Zhou C, Fu J, Gao B, Fu Y, Wang FS (2014) Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology 59:1331–1342. https://doi.org/10.1002/hep.26916CrossRefPubMed

122.

Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M (2000) Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132:517–524. https://doi.org/10.7326/0003-4819-132-7-200004040-00002CrossRefPubMed

123.

Guerret S, Desmoulière A, Chossegros P, Costa AMA, Badid C, Trépo C, Grimaud JA, Chevallier M (1999) Long-term administration of interferon-α in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years. J Viral Hepat 6:125–133. https://doi.org/10.1046/j.1365-2893.1999.00148.xCrossRefPubMed

124.

Di Bisceglie AM, Shiffman ML, Everson GT et al (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359:2429–2441. https://doi.org/10.1056/nejmoa0707615CrossRefPubMedPubMedCentral

125.

Laursen TL, Siggaard CB, Kazankov K, Sandahl TD, Møller HJ, Tarp B, Kristensen LH, Laursen AL, Leutscher P, Grønbæk H (2020) Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C. J Viral Hepat 27:28–35. https://doi.org/10.1111/jvh.13204CrossRefPubMed

126.

Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan-Garcia A, To N, Hong M, Chia A, Gill US, Kennedy PT, Tan KC, Lee KH, de Libero G, Gehring AJ, Willberg CB, Klenerman P, Bertoletti A (2014) Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog 10:1–13. https://doi.org/10.1371/journal.ppat.1004210CrossRef

127.

Wei H, Li F, Wei H et al (2013) Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. Gastroenterology 144:392–401. https://doi.org/10.1053/j.gastro.2012.10.039CrossRefPubMed

128.

Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, Wang Z, Wu Q, Peng H, Wei H, Sun R, Tian Z (2018) Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 19:723–732. https://doi.org/10.1038/s41590-018-0132-0CrossRefPubMed

129.

Xu L, Huang Y, Tan L, Yu W, Chen D, Lu CC, He J, Wu G, Liu X, Zhang Y (2015) Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol 29:635–641. https://doi.org/10.1016/j.intimp.2015.09.017CrossRefPubMed

130.

Okwor CIA, Oh JS, Crawley AM, Cooper CL, Lee SH (2020) Expression of inhibitory receptors on T and NK cells defines immunological phenotypes of HCV patients with advanced liver fibrosis. iScience 23:101513. https://doi.org/10.1016/j.isci.2020.101513CrossRefPubMedPubMedCentral

131.

Felices M, Kodal B, Hinderlie P, Kaminski MF, Cooley S, Weisdorf DJ, Vallera DA, Miller JS, Bachanova V (2019) Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. Blood Adv 3:897–907. https://doi.org/10.1182/bloodadvances.2018029371CrossRefPubMedPubMedCentral

132.

Albinger N, Hartmann J, Ullrich E (2021) Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. https://doi.org/10.1038/s41434-021-00246-w

133.

Pfefferle A, Huntington ND (2020) You have got a fast CAR: chimeric antigen receptor NK cells in cancer therapy. Cancers (Basel) 12:706. https://doi.org/10.3390/cancers12030706CrossRef

Title: The role of natural killer cells in liver inflammation
Authors: A. J. Highton
I. S. Schuster
M. A. Degli-Esposti
M. Altfeld
Publication date: 01-08-2021
Publisher: Springer Berlin Heidelberg
Keywords: Hepatitis
Fatty Liver
Published in: Seminars in Immunopathology / Issue 4/2021
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-021-00877-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

The two facets of gp130 signalling in liver tumorigenesis

Management of cell death in parasitic infections

Role of bile acids in inflammatory liver diseases

The contact system in liver injury

Functional heterogeneity of CD4+ T cells in liver inflammation

Mediators of liver inflammation and carcinogenesis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials